Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by WatchLearnEarnon Mar 20, 2018 10:57pm
92 Views
Post# 27750964

RE:RE:this is what its all about not GI safety

RE:RE:this is what its all about not GI safetyIt's not going to work loser, late-comer. The market already knows ATB-346 is a winner. All the little BS points you're trying to use to whittle away at investor confidence are long-known and closed issues.

HEALTH CANADA reviewed Ph. 1 results and the independent re-evaluation and approved Ph. 2. Even with the additional scrutiny coming from Ph. 1, the company has persevered and shown excellent Ph. 2 results.

Ph. 3 will be a success as well. The science is solid. The efficacy results will prove it out.

It WILL happen, but we may actually be bought out by then... So keep wasting your time, Little Boy Blew, these issues were churned over and over for many months when Ph. 1 was announced. 

Naproxen is out. 346 is in.



BlueCielo wrote:
in other subjects ??????....how many was other subjects with enzyme elevations


BlueCielo wrote: Additional liver enzyme elevations were observed in other subjects in the higher dose cohorts.  The Company is concerned that, when assessed together, these liver enzyme elevations are indicative of potential hepatotoxicity.  Pre-clinical studies on ATB-346 had provided no indication of potential hepatotoxicity at therapeutic doses. 




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities